急性病毒性肝炎住院患者血清学分型与流行病学分布研究

本文收集了西安市住院急性病毒性肝炎患者血清标本２９３份，用ＥＬＩＳＡ进行分型检测，并作流行病学调查。结果发现：甲肝占６５．１９％，乙肝占１０．９２％，丙肝占４．７８％，丁肝占３．７５％，戊肝占４．４４％，诊断不明者占１０．９２％。结果表明，在西安市住院的急性病毒性肝炎中，甲肝为主要类型；与以往结果比较，甲肝患者的发病年龄明显后移；除乙肝外，各型肝炎中男性均多于女性，尤以丁肝和戊肝为著；甲肝有明显的     

高原性蛋白尿与急性高原病关系的探讨

通过对34名平原人乘飞机进驻海拔4370m 高原后尿蛋白的动态分析和急性高原病(AMS)的调查,我们看到,受试者在达高原的1～3天内尿蛋白阳性率为20.6～26.5%,尿潜血反应阳性率为5.9～14.8%,4天后均接近平原值;AMS 者的尿蛋白浓度明显高于未患AMS 者(28.9±4.4v.s.17.1±2.2,p<0.05);在AMS 患者中,69.2%的人(9/13)尿蛋白阳性,30.8%的人(4/13)尿蛋白可疑,而且尿蛋白阳性者的AMS 症状持续的时间明显长于非尿蛋白阳性者(4.4±0.1v.s.3.6±0.1,p<0.05)。上述结果提示,平原人在快速进驻高原初期肾功能会受到严重影响,但经短期高原适应后是可以很快恢复的;AMS 与高原性蛋白尿有密切的关系;蛋白尿的产生可能是由肾小球基底膜受损后通透增加所致。     

Secondary hyperparathyroidism and acute tubular necrosis following renal transplantation

In the present study we investigated the relationship betweensecondary hyperparathyroidism in renal graft recipients andpost-transplantation acute tubular necrosis (ATN). Patientswere divided into two groups according to graft function: groupA consisted of 28 patients who had an uneventful postoperativeperiod and did not require haemodialysis. Group B comprised26 patients with primary non-function of the graft due to biopsy-provenATN who required continued haemodialysis for the first postoperativeweek or longer (mean 14.2 ±8.7 days). Both groups hadcomparable donor characteristics, HLA-matching and ischaemiatimes. All patients were given cyclospo-rin and low-dose prednisolonefor immunosuppression. Pretransplant levels of intact PTH weresignificantly greater in group B than in group A (203.5 ±193.1pg/ml versus 81.7±45.2 pg/ml, P<0.01). Group B patientshad more transplant biopsies (50 versus 7) and a longer hospitalizationtime (33.4 ± 10.9 days versus 21.9 ± 11.9 days,P<0.01), although serum creatinine on the day of dischargewas higher in group B (1.77 ± 0.51 mg/dl versus 1.5±0.45mg/dl, P<0.05). We conclude that patients with secondaryhyperparathyroidism as assessed by measuring circulating levelsof intact PTH have an increased incidence of ATN.     

Terminal acute myelogenous leukemia in a patient with congenital agranulocytosis

Congenital agranulocytosis terminating in acute myelogenous leukemia has been previously reported in only two cases of adolescent males. We describe the clinical and laboratory features of a 13-year-old male with congenital agranulocytosis, treated with G-CSF with initial good neutrophil response, who subsequently developed acute myeloid leukemia. This rare complication may define a preleukemic subset of patients for whom G-CSF therapy is ineffective. The diagnostic challenges of this case are presented.     

Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial

Abstract. Objectives. To evaluate the efficacy of self-administered subcutaneous sumatriptan in the acute treatment of early-morning migraine attacks. Design. A double-blind, randomized, placebo-controlled, cross-over study. Setting. Thirteen neurology centres in France. Subjects. Patients of either sex, 18–65 years old, with two to six attacks of migraine (according to the International Headache Society (IHS) criteria, with or without aura) per month, of which at least two had to be early-morning migraine attacks. One-hundred-and-one patients were included, 96 being evaluable for the first attack and 81 for the cross-over design. Interventions. Two migraine attacks (grade 2/3) were treated with sumatriptan (6 mg) or placebo, with an optional second injection 1–24 h later. Main outcome measures. The primary end-point was headache relief: reduction in headache severity from grade 2/3 (moderate/severe) to grade 1/0 (mild/none) 2 h after treatment. Results. Sumatriptan was superior to placebo for headache relief (32 [78%] vs. 11 [28%] at the first attack; 29 [73%] vs. 8 [20%] at the second; P < 0.001). Because of a significant carry-over effect for some of the secondary end-points, a parallel-group analysis of the first attack was performed, which confirmed a significantly higher efficacy of sumatriptan for all end-points: pain-free rate (22 [46%] vs. 7 [15%]; P = 0.001) and use of a second injection (26 [53%] vs. 38 [81%]; P = 0.004). Sumatriptan was preferred by 74% of patients vs. 17% for placebo, and 9% expressed no preference (P < 0.0001). After complete relief, headache reappeared in 8/23 (35%) patients with sumatriptan and 3/7 (43%) with placebo. Adverse events were significantly more frequent with sumatriptan but they were minor and transient. Conclusion. Subcutaneous sumatriptan auto-injection is an effective and well-tolerated acute treatment of early-morning migraine attacks allowing earlier return to normal activity.     

慢性阻塞性肺疾病患者外周血单个核细胞CD36 mRNA、血清ApoE水平对急性加重期发生的预测价值

目的：分析慢性阻塞性肺疾病（COPD）患者外周血单个核细胞（PBMCs）白细胞分化抗原36（CD36）信使核糖核酸（mRNA）、血清载脂蛋白E（ApoE）水平对急性加重期发生的预测价值。方法：选取2021年6月-2022年5月在湖州市中心医院就诊的COPD患者96例,其中急性加重期COPD患者为AECOPD组（n=50）,稳定期COPD患者为稳定组（n=46）,选取健康人群40例为对照组。检测所有受试者血清炎性因子[肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）-6、IL-1β、C反应蛋白（CRP）]、ApoE、肺功能指标[第1秒用力呼气容积与用力肺活量的比值（FEV1/FVC）、第1秒用力呼气容积占预计值百分比（FEV1%pred）]和PBMCs中CD36 mRNA水平;分析COPD患者PBMCs中CD36 mRNA、血清ApoE水平与炎性因子、肺功能指标的相关性以及PBMCs中CD36 mRNA、血清ApoE对COPD患者急性加重期发生的预测价值。结果：对照组、稳定组、AECOPD组吸烟史比例、TNF-α、IL-6、IL-1β、CRP、PBMCs中CD36 mRNA和血清ApoE水平依次升高,FEV1/FVC、FEV1%pred水平依次降低（P＜0.05）;COPD患者PBMCs中CD36 mRNA与血清ApoE水平呈正相关（P＜0.05）,COPD患者PBMCs中CD36 mRNA、血清ApoE水平均与血清TNF-α、IL-6、IL-1β、CRP呈正相关（P＜0.05）,与FEV1/FVC、FEV1%pred呈负相关（P＜0.05）;PBMCs中CD36 mRNA单独、血清ApoE单独、二者联合预测COPD患者急性加重期发生的曲线下面积（AUC）分别为0.887、0.871、0.966,二者联合预测的AUC高于CD36 mRNA、ApoE单独预测的AUC（P＜0.05）。结论：COPD患者PBMCs中CD36 mRNA和血清ApoE均呈高表达,二者对COPD患者急性加重期发生具有一定的预测价值。     

EFFECTS OF ACUTE AND CHRONIC ADMINISTRATION OF TWO ANTIBIOTICS, AZTREONAM AND GENTAMICIN, ALONE OR IN COMBINATION, ON "OPEN-FIELD TEST" IN MICE

A study aimed at investigating the behavioural effects of aztreonam and gentamicin, given separately or in combination, was carried out in mice. Animals were randomly assigned to two test conditions: acute and chronic treatment. Those receiving acute treatment had a single IP injection 60 min before the test. Those receiving chronic treatment had IP injections once daily for 5 successive days prior to the test. Behavioural patterns (ambulation, rearing, grooming and defecation) were assessed using the "open-field" test. The results indicate that, both after single and multiple dosing, aztreonam (10, 40 and 80 mg/kg IP) and/or gentamicin (10 mg/kg IP) do produce changes in the behaviour of animals. A rate increasing effect for certain behaviours (rearing, grooming and defecation) and a reduction in other behaviours (ambulation) seems to occur.     

A patient with hepatic granuloma formation and angiotensin-converting enzyme production by granuloma cells during clinical relapse of hepatitis A

Elevation of the serum angiotensin-converting enzyme (sACE) level and hepatic granulomas were found during a clinical relapse in a 22 year old patient with acute viral hepatitis type A (AVH-A). The serum transaminase level and sACE level remained high for more than 6 months. In the biopsied specimen of the liver, fibrous rings of granulomas composed of collagen types I, III, and V were observed. Furthermore, the localization of ACE was visible in the rough endoplasmic reticulum of epithelioid cells of granulomas in the liver under electron microscopy using the indirect immunoperoxidase method. These results suggest that granuloma cells in the liver caused by hepatitis A may be involved in ACE production. In addition, other diseases associated with the presence of granulomas in the liver, such as lymphoma, cytomegalovirus infection, visceral leishmaniasis, and lupoid hepatitis, were ruled out. However, the hepatic granulomas disappeared with the healing of AVH-A. In this regard, the present case is considered to be one of the very few cases of hepatic sarcoidosis.     

Monoclonal antibodies against human granulocytes and myeloid differentiation antigens

Monoclonal antibodies (MCA) were obtained by immunizing BALB/c mice with 99% pure granulocytes from normal donors or with a whole leukocyte suspension obtained from a chronic myelogenous leukemia (CML) patient, and then fusing the mouse spleen cells with a 315–43 myeloma cell clone. Four MCA were selected and studied using ELISA, immunofluorescence, cytotoxicity assays, and FACS analysis. Antibodies 80H.1. 80H.3. and 80H.5 (from normals) and 81H.1 (from CML) detected antigens expressed on neutrophils. Antibodies 80H.1 and 80H.3 (lgG) also reacted with monocytes but not with other blood cell subsets. Antibodies 80H.5 and 81H.1 (lgM) were cytotoxic and reacted strongly with most of the cells of the neutrophil maturation sequence. i.e., myeloblasts, promyelocytes, myelocytes, and mature granulocytes. Antibodies 80H.5 and 81H.1 also inhibited BFU-GM and CFU-E. Antigens recognized by 80H.3. 80H.5, and 81H.1 were expressed both on a proportion of cells from HL.60, KG.1, ML.1, and K562 myeloid cell lines, and on a proportion of blast cells isolated from patients with acute myelogenous leukemia. They were not found on lymphoid cell lines or lymphoid leukemia cells. These MCA recognize either late differentiation antigens expressed on mature neutrophils and monocytes (80H.1 and 80H.3) or early differentiation antigens (80H.5 and 81H.1) specific to the granulocytic lineage. They may be useful for a better definition of those antigens specific to hematopoietic stem cells and their relationship with normal or neoplastic hematopoiesis.     

Donor characteristics do not influence transfusion-related acute lung injury incidence in a secondary analysis of two case-control studies

Objective

To investigate the relation between donor characteristics and TRALI incidence.